Table 1.
Relationship between MMP-2 mRNA expression and clinicopathologic and uPA system parameters.
| Variable | Case number | Expression of MMP-2 mRNA, n (%) | χ2 | P |
| Depth of invasion | ||||
| Early cancer | 11 | 3 (27.3) | 1.91 | >0.05 |
| Advanced cancer | 56 | 28 (50.0) | ||
| Differentiation | ||||
| Well-moderate | 16 | 6 (43.8) | 0.65 | >0.05 |
| Poor | 51 | 25 (47.1) | ||
| Lymph node metastasis | ||||
| Positive | 21 | 13 (61.9) | 7.61 | <0.01 |
| Negative | 46 | 18 (39.1) | ||
| Liver metastasis | ||||
| Positive | 8 | 6 (75.0) | 3.01 | >0.05 |
| Negative | 59 | 25 (42.4) | ||
| TNM stage | ||||
| I+II | 13 | 3 (23.1) | 3.49 | >0.05 |
| III+IV | 54 | 28 (51.9) | ||
| Lauren's classification | ||||
| Diffuse/mixed types | 48 | 26 (54.2) | 4.25 | <0.05 |
| Intestinal type | 19 | 5 (26.3) | ||
| uPA mRNA | ||||
| Positive | 49 | 27 (55.1) | 5.72 | <0.05 |
| Negative | 18 | 4 (22.2) | ||
| uPA-R mRNA | ||||
| Positive | 51 | 28 (54.9) | 6.40 | <0.05 |
| Negative | 16 | 3 (18.8) |